Cargando…

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival

BACKGROUND: We performed a multicenter retrospective observational study to investigate the impact of clinical–pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma. PATIENTS AND METHODS: A total of 305...

Descripción completa

Detalles Bibliográficos
Autores principales: Mannavola, Francesco, Mandala, Mario, Todisco, Annalisa, Sileni, Vanna Chiarion, Palla, Marco, Minisini, Alessandro Marco, Pala, Laura, Morgese, Francesca, Di Guardo, Lorenza, Stucci, Luigia Stefania, Guida, Michele, Indini, Alice, Quaglino, Pietro, Ferraresi, Virginia, Marconcini, Riccardo, Tronconi, Maria Chiara, Rossi, Ernesto, Nigro, Olga, Occelli, Marcella, Cortellini, Alessio, Quadrini, Silvia, Palmieri, Giuseppe, Pigozzo, Jacopo, Ascierto, Paolo Antonio, Vitale, Maria Grazia, Strippoli, Sabino, Ferrucci, Pier Francesco, Berardi, Rossana, Randon, Giovanni, Cardone, Pietro, Schinzari, Giovanni, Silvestris, Franco, Tucci, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523509/
https://www.ncbi.nlm.nih.gov/pubmed/33042809
http://dx.doi.org/10.3389/fonc.2020.01652
_version_ 1783588393349808128
author Mannavola, Francesco
Mandala, Mario
Todisco, Annalisa
Sileni, Vanna Chiarion
Palla, Marco
Minisini, Alessandro Marco
Pala, Laura
Morgese, Francesca
Di Guardo, Lorenza
Stucci, Luigia Stefania
Guida, Michele
Indini, Alice
Quaglino, Pietro
Ferraresi, Virginia
Marconcini, Riccardo
Tronconi, Maria Chiara
Rossi, Ernesto
Nigro, Olga
Occelli, Marcella
Cortellini, Alessio
Quadrini, Silvia
Palmieri, Giuseppe
Pigozzo, Jacopo
Ascierto, Paolo Antonio
Vitale, Maria Grazia
Strippoli, Sabino
Ferrucci, Pier Francesco
Berardi, Rossana
Randon, Giovanni
Cardone, Pietro
Schinzari, Giovanni
Silvestris, Franco
Tucci, Marco
author_facet Mannavola, Francesco
Mandala, Mario
Todisco, Annalisa
Sileni, Vanna Chiarion
Palla, Marco
Minisini, Alessandro Marco
Pala, Laura
Morgese, Francesca
Di Guardo, Lorenza
Stucci, Luigia Stefania
Guida, Michele
Indini, Alice
Quaglino, Pietro
Ferraresi, Virginia
Marconcini, Riccardo
Tronconi, Maria Chiara
Rossi, Ernesto
Nigro, Olga
Occelli, Marcella
Cortellini, Alessio
Quadrini, Silvia
Palmieri, Giuseppe
Pigozzo, Jacopo
Ascierto, Paolo Antonio
Vitale, Maria Grazia
Strippoli, Sabino
Ferrucci, Pier Francesco
Berardi, Rossana
Randon, Giovanni
Cardone, Pietro
Schinzari, Giovanni
Silvestris, Franco
Tucci, Marco
author_sort Mannavola, Francesco
collection PubMed
description BACKGROUND: We performed a multicenter retrospective observational study to investigate the impact of clinical–pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma. PATIENTS AND METHODS: A total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician’s practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal-related events (SREs), and different treatments on both overall survival (OS) and time-to-SREs. The chi-squared test evaluated the suitability of several parameters to predict the occurrence of SREs. RESULTS: Eighty-three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty-seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma-associated factor was predictive of the development of SREs, although patients receiving early treatment with bone-targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT. CONCLUSION: Based on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation.
format Online
Article
Text
id pubmed-7523509
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75235092020-10-09 An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival Mannavola, Francesco Mandala, Mario Todisco, Annalisa Sileni, Vanna Chiarion Palla, Marco Minisini, Alessandro Marco Pala, Laura Morgese, Francesca Di Guardo, Lorenza Stucci, Luigia Stefania Guida, Michele Indini, Alice Quaglino, Pietro Ferraresi, Virginia Marconcini, Riccardo Tronconi, Maria Chiara Rossi, Ernesto Nigro, Olga Occelli, Marcella Cortellini, Alessio Quadrini, Silvia Palmieri, Giuseppe Pigozzo, Jacopo Ascierto, Paolo Antonio Vitale, Maria Grazia Strippoli, Sabino Ferrucci, Pier Francesco Berardi, Rossana Randon, Giovanni Cardone, Pietro Schinzari, Giovanni Silvestris, Franco Tucci, Marco Front Oncol Oncology BACKGROUND: We performed a multicenter retrospective observational study to investigate the impact of clinical–pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma. PATIENTS AND METHODS: A total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician’s practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal-related events (SREs), and different treatments on both overall survival (OS) and time-to-SREs. The chi-squared test evaluated the suitability of several parameters to predict the occurrence of SREs. RESULTS: Eighty-three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty-seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma-associated factor was predictive of the development of SREs, although patients receiving early treatment with bone-targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT. CONCLUSION: Based on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation. Frontiers Media S.A. 2020-09-15 /pmc/articles/PMC7523509/ /pubmed/33042809 http://dx.doi.org/10.3389/fonc.2020.01652 Text en Copyright © 2020 Mannavola, Mandala, Todisco, Sileni, Palla, Minisini, Pala, Morgese, Di Guardo, Stucci, Guida, Indini, Quaglino, Ferraresi, Marconcini, Tronconi, Rossi, Nigro, Occelli, Cortellini, Quadrini, Palmieri, Pigozzo, Ascierto, Vitale, Strippoli, Ferrucci, Berardi, Randon, Cardone, Schinzari, Silvestris and Tucci. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mannavola, Francesco
Mandala, Mario
Todisco, Annalisa
Sileni, Vanna Chiarion
Palla, Marco
Minisini, Alessandro Marco
Pala, Laura
Morgese, Francesca
Di Guardo, Lorenza
Stucci, Luigia Stefania
Guida, Michele
Indini, Alice
Quaglino, Pietro
Ferraresi, Virginia
Marconcini, Riccardo
Tronconi, Maria Chiara
Rossi, Ernesto
Nigro, Olga
Occelli, Marcella
Cortellini, Alessio
Quadrini, Silvia
Palmieri, Giuseppe
Pigozzo, Jacopo
Ascierto, Paolo Antonio
Vitale, Maria Grazia
Strippoli, Sabino
Ferrucci, Pier Francesco
Berardi, Rossana
Randon, Giovanni
Cardone, Pietro
Schinzari, Giovanni
Silvestris, Franco
Tucci, Marco
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
title An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
title_full An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
title_fullStr An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
title_full_unstemmed An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
title_short An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
title_sort italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523509/
https://www.ncbi.nlm.nih.gov/pubmed/33042809
http://dx.doi.org/10.3389/fonc.2020.01652
work_keys_str_mv AT mannavolafrancesco anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT mandalamario anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT todiscoannalisa anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT silenivannachiarion anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT pallamarco anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT minisinialessandromarco anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT palalaura anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT morgesefrancesca anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT diguardolorenza anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT stucciluigiastefania anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT guidamichele anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT indinialice anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT quaglinopietro anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT ferraresivirginia anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT marconciniriccardo anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT tronconimariachiara anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT rossiernesto anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT nigroolga anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT occellimarcella anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT cortellinialessio anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT quadrinisilvia anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT palmierigiuseppe anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT pigozzojacopo anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT asciertopaoloantonio anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT vitalemariagrazia anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT strippolisabino anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT ferruccipierfrancesco anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT berardirossana anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT randongiovanni anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT cardonepietro anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT schinzarigiovanni anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT silvestrisfranco anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT tuccimarco anitalianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT mannavolafrancesco italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT mandalamario italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT todiscoannalisa italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT silenivannachiarion italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT pallamarco italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT minisinialessandromarco italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT palalaura italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT morgesefrancesca italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT diguardolorenza italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT stucciluigiastefania italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT guidamichele italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT indinialice italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT quaglinopietro italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT ferraresivirginia italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT marconciniriccardo italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT tronconimariachiara italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT rossiernesto italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT nigroolga italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT occellimarcella italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT cortellinialessio italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT quadrinisilvia italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT palmierigiuseppe italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT pigozzojacopo italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT asciertopaoloantonio italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT vitalemariagrazia italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT strippolisabino italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT ferruccipierfrancesco italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT berardirossana italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT randongiovanni italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT cardonepietro italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT schinzarigiovanni italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT silvestrisfranco italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival
AT tuccimarco italianretrospectivesurveyonbonemetastasisinmelanomaimpactofimmunotherapyandradiotherapyonsurvival